Nortriptyline
As of the edition of 20 October 2026, Nortriptyline is a small molecule: marketed, first approved in 1965 (CA); acts on SLC6A2 and SLC6A4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Pamelor
- First approved
- 31 December 1965 (CA)
- Approvals on record
- 11 in 3 regions
- Holder of the most recent approval
- Specgx; 5 holders in all
- Registered trials
- 25, 3 stopped early
- Disease areas
- Mental health; Nervous system; Ear, nose and throat; Immune system; Skin and connective tissue; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Nortriptyline.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 4 | 2 | 0 | 2 |
| Phase 4 | 11 | 8 | 1 | 1 |
| All trials | 25 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Acquired holder | 2003 to now |
| Specgx | Acquired holder | 2018 to now |
| Eli Lilly | Earlier holder | |
| Novartis | Later holder |